Dear Client,
As part of our ongoing commitment to ensuring the security of your online trading experience, we would like to inform you of our protocol for addressing any suspicious activities observed on your trading account
Should you notice any irregularities or suspect unauthorized access to your account, we kindly request that you take immediate action by following the steps outlined below:
Send an Email Please send an email to stoptrade@acml.in from your registered email ID. In the email, briefly outline the suspicious activity you have observed.
Phone Call Alternatively, you can call us at 07968101000 Ext: 1 from your registered mobile number. This will enable us to address your concerns promptly.
When contacting us, please ensure you provide the following details:
By providing this information, you enable us to swiftly investigate and take appropriate measures to safeguard your account.
Your security and peace of mind are of utmost importance to us, and we appreciate your cooperation in maintaining the integrity of your trading account.
Also, the US drug regulator conducted a routine current good manufacturing practice (cGMP) inspection at the formulations manufacturing facility (FTO-3) in Bachupally, Hyderabad from 19 October to 27 October 2023. The facility was issued a Form 483 with ten observations on 28 October 2023.
The drug maker stated that both the inspections have received ?voluntary action indicated? (VAI) from the USFDA, indicating that the inspection is closed.
Dr Reddy's Laboratories is engaged in providing medicines. The firm operates in three segments: global generics, pharmaceutical services and active ingredients (PSAI) and proprietary products.
The drug major's consolidated net profit increased 10.57% to Rs 1,378.9 crore on 6.57% rise in revenues to Rs 7,214.8 crore in Q3 FY24 over Q3 FY23.
The counter hit a life-time high of Rs 6,390 in today?s intraday session.
Powered by Capital Market - Live News